Letters to the Editor

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

Department of Hematology, Hôpital Haut-Lévêque, University Hospital Bordeaux, Pessac
Hematology, University Hospital Ghent, Ghent
Service d'Hématologie Clinique, University Hospital Hôtel-Dieu, Nantes
Service d’Hématologie Clinique, /IUC Oncopole, Toulouse
Hémopathies Lymphoïdes, Hôpital Henri Mondor, Creteil
CHU de Tours, Hôpital de Bretonneau, Tours
CHU Dijon, Hôpital Du Bocage, Dijon
University of Lille, CHU Lille, Service des Maladies du Sang, Lille
Sorbonne Université, INSERM, UMR_S 938, Centre de Recherche Saint-Antoine, Team Proliferation and Differentiation of Stem Cells, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpetrière, Département d'Hématologie, Paris
Institut Curie Paris, Paris
Institut Paoli-Calmettes, Marseille
CHU de Reims,Hôpital Robert Debré, Reims
CHD Vendée, La Roche-sur-Yon
Zuyderland MC, Sittard
Northwest Clinics, Alkmaar
Biostatistical Department, Hôpital Saint Louis, Paris
Janssen Research and Development, LLC, Raritan, NJ
Janssen Research and Development, Beerse
Janssen Research and Development, LLC, Leiden
Janssen Research and Development, LLC, Leiden
Janssen Research and Development, LLC, Leiden
Erasmus University Medical Center Cancer Institute, Rotterdam
Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Amsterdam
Haematologica Early view Mar 4, 2021 https://doi.org/10.3324/haematol.2020.261842